METABOLIC AND HORMONAL RISK FACTORS FOR ENDOMETRIAL  HYPERPLASIA IN REPRODUCTIVE-AGE WOMEN: A CRITICAL  INTEGRATIVE REVIEW OF PATHOBIOLOGY, REAL-WORLD  EVIDENCE AND PRECISION RISK ASSESSMENT

Xolboyeva Mashhura

Authors

Xolboyeva Mashhura

Keywords:

endometrial hyperplasia; endometrial intraepithelial neoplasia; atypical hyperplasia; obesity; insulin resistance; chronic anovulation; polycystic ovary syndrome; estrogen; progesterone; metabolic syndro me; real-world evidence; causal inference; artificial intelligence; fertility preservation.

Abstract

Endometrial hyperplasia in reproductive-age women encompasses biologically heterogeneous lesions whose risk is shaped by chronic anovulation, unopposed estrogen exposure, adiposity, insulin resistance, diabetes and associated inflammation. The clinical distinction between hyperplasia without atypia and endometrial intraepithelial neoplasia/atypical endometrial hyperplasia (EIN/AEH) is essential because the latter can coexist with or precede carcinoma. Objective: To critically integrate mechanistic, clinical and regulatory evidence linking metabolic and hormonal exposures to endometrial proliferative disorders and to propose a transparent real-world research framework. Methods:

Downloads

Download data is not yet available.

References

1. American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus–Gynecology. Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735–744. doi:10.1097/AOG.0000000000005297.

2. Ring KL, Mills AM, Modesitt SC. Endometrial hyperplasia. Obstet Gynecol. 2022;140(6):1061–1075. doi:10.1097/AOG.0000000000004989.

3. Royal College of Obstetricians and Gynaecologists. Management of endometrial hyperplasia. Green-top Guideline No. 67. London: RCOG; 2016. Available from: https://www.rcog.org.uk/guidance/browse-all-guidance/green-topguidelines/management-of-endometrial-hyperplasia-green-top-guideline no-67/

4. Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020;(9):CD012658. doi:10.1002/14651858.CD012658.pub2.

5. US Food and Drug Administration. Real-world evidence. Silver Spring: FDA. Available from: https://www.fda.gov/science-research/science-and-research-specialtopics/real-world-evidence